Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520

  Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis
  B Candidate ARC-520

                   *Live event on March 25 at 12:30-2:00 EST
  *Audio and slide presentation also available by conference call and webcast

Business Wire

PASADENA, Calif. -- March 7, 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics
company, today announced that it will host an analyst and investor event on
Monday, March 25, from 12:30 to 2:00 p.m. EST in New York City. The company
will present an overview of its RNAi-based drug candidate ARC-520 for the
treatment of chronic hepatitis B virus (HBV) infection including preclinical
data, HBV disease biology, clinical trial strategy and timelines, market
opportunity, clinician and patient perspectives, and new data generated from a
chimpanzee with chronic HBV infection.

Presenters are: Dr. Robert Gish, Chairman of Arrowhead’s HBV Clinical Advisory
Board; other key opinion leaders from the HBV community; Dr. Chris Anzalone,
Arrowhead’s President and CEO; and Dr. Bruce Given, Arrowhead’s COO and Head
of R&D. The presentation will be broadcast live by webcast and conference
call, and it will also be archived on the company website.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics
company with development programs in oncology, obesity, and chronic hepatitis
B virus infection. The company is leveraging its platform technologies to
design and develop peptide-drug conjugates (PDCs) that specifically home to
cell types of interest while sparing off-target tissues, create targeted drugs
based on the gene silencing RNA interference (RNAi) mechanism, and work with
partners to create improved versions of traditional small molecule drugs.

For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to ir@arrowres.com

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and completing
clinical trials, rapid technological change in our markets, and the
enforcement of our intellectual property rights. Arrowhead Research
Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume
no obligation to update or revise forward-looking statements to reflect new
events or circumstances.

Contact:

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
or
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
 
Press spacebar to pause and continue. Press esc to stop.